| Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer F Ye, S Dewanjee, Y Li, NK Jha, ZS Chen, A Kumar, Vishakha, T Behl, ... Molecular cancer 22 (1), 105, 2023 | 120 | 2023 |
| Understanding the mechanistic pathways and clinical aspects associated with protein and gene based biomarkers in breast cancer T Behl, A Kumar, A Sehgal, S Singh, N Sharma, S Yadav, S Rashid, N Ali, ... International Journal of Biological Macromolecules, 126595, 2023 | 5 | 2023 |
| A review on silver nanoparticles focusing on applications in biomedical sector A Kumar, R Bhatia Int J Pharm Sci Dev Res 8 (1), 057-063, 2022 | 4 | 2022 |
| Design, synthesis, molecular docking, and biological evaluation of isatin-based fused heterocycles as epidermal growth factor receptor inhibitors A Kumar, B Kumar, R Bhatia ASSAY and Drug Development Technologies 21 (5), 222-233, 2023 | 3 | 2023 |
| Recent advancements in NS5B inhibitors (2011-2021): Structural insights, SAR studies and clinical status A Kumar, R Bhatia Journal of Molecular Structure, 136272, 2023 | 1 | 2023 |
| Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions M Zheng, A Kumar, V Sharma, T Behl, A Sehgal, P Wal, NV Shinde, ... Frontiers in Cell and Developmental Biology 12, 1353860, 2024 | | 2024 |
| Computational insights into KRAS G12C inhibition: exploring possible repurposing of Azacitidine and Ribavirin V Sharma, A Kumar, R Rawat, M Gulati, T Behl, A Khalid, A Najmi, ... Journal of Biomolecular Structure and Dynamics, 1-11, 2024 | | 2024 |
| Impact of epidermal growth factor receptors as a key clinical target against cancer A Kumar, RK Narang, RK Bhatia Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy, 139-159, 2024 | | 2024 |
| Impact of Cannabinoid Receptors in the Design of Therapeutic Agents against Human Ailments A Kumar, O Gupta, R Bhatia, V Monga Current Topics in Medicinal Chemistry 23 (19), 1807-1834, 2023 | | 2023 |
